Fgfr Inhibitors | List of Frontiers open access articles

Review

Published on 08 Jul 2024

Fibroblast growth factor receptor signaling in estrogen receptor-positive breast cancer: mechanisms and role in endocrine resistance

in Cancer Cell Signaling

Arnaldo Marin
Fernanda Morales
Benjamín Walbaum

Frontiers in Oncology

doi 10.3389/fonc.2024.1406951

8,260 views
8 citations

Review

Published on 14 Apr 2022

Signaling Pathway and Small-Molecule Drug Discovery of FGFR: A Comprehensive Review

in Chemical Biology

Jia Zheng
Wei Zhang
Linfeng Li
Yi He
Yue Wei
Yongjun Dang
Shenyou Nie
Zufeng Guo

Frontiers in Chemistry

doi 10.3389/fchem.2022.860985

26,683 views
66 citations

Original Research

Published on 26 Mar 2019

Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines

in Cancer Molecular Targets and Therapeutics

Claudia Fumarola
Nicole Bozza
Riccardo Castelli
Francesca Ferlenghi
Giuseppe Marseglia
Alessio Lodola
Mara Bonelli
Silvia La Monica
Daniele Cretella
Roberta Alfieri

Frontiers in Oncology

doi 10.3389/fonc.2019.00179

14,980 views
45 citations

Original Research

Published on 20 Nov 2024

The FGFR inhibitor Rogaratinib reduces microglia reactivity and synaptic loss in TBI

in Multiple Sclerosis and Neuroimmunology

Rida Rehman
Albrecht Froehlich
Florian olde Heuvel
Lobna Elsayed
Tobias Boeckers
Markus Huber-Lang
Cristina Morganti-Kossmann
Francesco Roselli

Frontiers in Immunology

doi 10.3389/fimmu.2024.1443940

4,531 views
4 citations

Case Report

Published on 07 Apr 2025

Case Report: FGFR2 inhibitor resistance via PIK3CA and CDKN2A/B in an intrahepatic cholangiocarcinoma patient with FGFR2-SH3GLB1 fusion

in Cancer Molecular Targets and Therapeutics

Nadja Ballin
Alexander Ott
Olga Seibel-Kelemen
Irina Bonzheim
Dominik Nann
Janina Beha
Stephan Spahn
Stephan Singer
Stephan Ossowski
Cristiana Roggia

Frontiers in Oncology

doi 10.3389/fonc.2025.1527484

2,998 views
2 citations

Original Research

Published on 11 May 2021

Targeted Therapy With PI3K and FGFR Inhibitors on Human Papillomavirus Positive and Negative Tonsillar and Base of Tongue Cancer Lines With and Without Corresponding Mutations

in Head and Neck Cancer

Stefan Holzhauser
Nicole Wild
Mark Zupancic
Ramona G. Ursu
Cinzia Bersani
Anders Näsman
Ourania N. Kostopoulou
Tina Dalianis

Frontiers in Oncology

doi 10.3389/fonc.2021.640490

15,189 views
28 citations

Original Research

Published on 10 Feb 2023

FGFR inhibitors combined with nab-paclitaxel - A promising strategy to treat non-small cell lung cancer and overcome resistance

in Molecular and Cellular Oncology

Feng Ma
Xinhai Zhu
Yuchun Niu
Aitao Nai
Shoaib Bashir
Yan Xiong
Yunlong Dong
Yin Li
Jian Song
Meng Xu

Frontiers in Oncology

doi 10.3389/fonc.2023.1088444

4,520 views
4 citations

Review

Published on 02 Sep 2022

Neoadjuvant Systemic Therapies in Bladder Cancer

in Urologic Oncology

Carissa E. Chu
Gopa Iyer
Bernard H. Bochner

Frontiers in Urology

doi 10.3389/fruro.2022.890761

4,081 views
1 citation

Original Research

Published on 22 Jul 2020

Disruption of FGF Signaling Ameliorates Inflammatory Response in Hepatic Stellate Cells

in Signaling

Cong Wang
Yuelong Li
Hao Li
Yali Zhang
Zhangguo Ying
Xuye Wang
Tingting Zhang
Wenshu Zhang
Zhichao Fan
Xiaokun Li

Frontiers in Cell and Developmental Biology

doi 10.3389/fcell.2020.00601

7,430 views
35 citations

Original Research

Published on 04 Apr 2024

Fibroblast growth factor receptor inhibitors mitigate the neuropathogenicity of Borrelia burgdorferi or its remnants ex vivo

in Microbial Immunology

Geetha Parthasarathy

Frontiers in Immunology

doi 10.3389/fimmu.2024.1327416

8,204 views
6 citations

Original Research

Published on 09 Dec 2021

Role of FGF Receptors and Their Pathways in Adrenocortical Tumors and Possible Therapeutic Implications

in Cancer Endocrinology

Iuliu Sbiera
Stefan Kircher
Barbara Altieri
Kerstin Lenz
Constanze Hantel
Martin Fassnacht
Silviu Sbiera
Matthias Kroiss

Frontiers in Endocrinology

doi 10.3389/fendo.2021.795116

4,464 views
9 citations

Original Research

Published on 14 Sep 2022

Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020

in Cancer Molecular Targets and Therapeutics

Jeffrey J. Kooijman
Wilhelmina E. van Riel
Jelle Dylus
Martine B. W. Prinsen
Yvonne Grobben
Tessa J. J. de Bitter
Antoon M. van Doornmalen
Janneke J. T. M. Melis
Joost C. M. Uitdehaag
Yugo Narumi

Frontiers in Oncology

doi 10.3389/fonc.2022.953013

13,818 views
20 citations

Original Research

Published on 05 Jun 2025

Erdafitinib diminishes LPS-mediated neuroinflammatory responses through NLRP3 in wild-type mice

in Inflammation Pharmacology

Hyun-ju Lee
Se Ha Kim
Tae-Mi Jung
Yu-Jin Kim
Chan-Hu Gu
Yoo Joo Jeong
Jeong-Heon Song
Hyang-Sook Hoe

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1572604

3,920 views
1 citation

Review

Published on 03 Dec 2021

Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review

in Cancer Immunity and Immunotherapy

Matthieu Roulleaux Dugage
Elise F. Nassif
Antoine Italiano
Rastislav Bahleda

Frontiers in Immunology

doi 10.3389/fimmu.2021.775761

30,514 views
80 citations

Articles

Fibroblast growth factor receptor signaling in estrogen receptor-positive breast cancer: mechanisms and role in endocrine resistance

Signaling Pathway and Small-Molecule Drug Discovery of FGFR: A Comprehensive Review

Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines

The FGFR inhibitor Rogaratinib reduces microglia reactivity and synaptic loss in TBI

Case Report: FGFR2 inhibitor resistance via PIK3CA and CDKN2A/B in an intrahepatic cholangiocarcinoma patient with FGFR2-SH3GLB1 fusion

Targeted Therapy With PI3K and FGFR Inhibitors on Human Papillomavirus Positive and Negative Tonsillar and Base of Tongue Cancer Lines With and Without Corresponding Mutations

FGFR inhibitors combined with nab-paclitaxel - A promising strategy to treat non-small cell lung cancer and overcome resistance

Neoadjuvant Systemic Therapies in Bladder Cancer

Disruption of FGF Signaling Ameliorates Inflammatory Response in Hepatic Stellate Cells

Fibroblast growth factor receptor inhibitors mitigate the neuropathogenicity of Borrelia burgdorferi or its remnants ex vivo

Role of FGF Receptors and Their Pathways in Adrenocortical Tumors and Possible Therapeutic Implications

Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020

Erdafitinib diminishes LPS-mediated neuroinflammatory responses through NLRP3 in wild-type mice

Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review